Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F1JY
|
|||
| Former ID |
DIB007825
|
|||
| Drug Name |
LAS-186323
|
|||
| Synonyms |
DHODH inhibitor (autoimmune disease), Alimirall; DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), Almirall
Click to Show/Hide
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1 | [1] | |
| Company |
Almirall Prodesfarma SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dihydroorotate dehydrogenase (DHODH) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Pyrimidine metabolism | |||
| Metabolic pathways | ||||
| Panther Pathway | De novo pyrimidine ribonucleotides biosythesis | |||
| Pathwhiz Pathway | Pyrimidine Metabolism | |||
| Reactome | Pyrimidine biosynthesis | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028859) | |||
| REF 2 | Clinical pipeline report, company report or official report of Aslanpharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.